The Effect of Intravenous Iron Treatment on Quality of Life in Inflammatory Bowel Disease Patients with Nonanemic Iron Deficiency

Table 2

Comparison of quality of life parameters before and after intravenous FeS treatment.

	Baseline	Follow-up
	Mean ± SD	Mean ± SD
Total ()
IBDQ	152.3 ± 30.6	162.3 ± 25.5	<0.001
SF-36 PCS	46.7 ± 7.3	49.3 ± 6.4	<0.001
SF-36 MCS	45.7 ± 9.8	47.6 ± 8.9	0.024
UC ()
IBDQ	147.4 ± 33.0	160.33 ± 28.7	<0.001
SF-36 PCS	45.7 ± 7.8	48.7 ± 6.9	<0.001
SF-36 MCS	45.1 ± 10.5	47.2 ± 9.5	0.045
CD ()
IBDQ	161.1 ± 23.4	166 ± 18	0.049
SF-36 PCS	48.3 ± 6.1	50.6 ± 5.3	0.010
SF-36 MCS	46.7 ± 8.3	48.2 ± 8.1	0.462

FeS: iron sucrose, SD: standard deviation, IBDQ: Inflammatory Bowel Disease Questionnaire, SF: short form, PCS: Physical Component Summary, MCS: Mental Component Summary, UC: ulcerative colitis, and CD: Crohn’s disease.